Pistoia Alliance predicts surge in life science quantum computing research

The not-for-profit also suggests the new year will see a "renewed focus" on the fight against antimicrobial resistance

The Pistoia Alliance, a not-for-profit alliance for life science R&D, has outlined its predictions for the life sciences industry in 2022. The predictions come from three recently appointed theme leads for the company, aimed to drive collaboration efforts across three key themes.

Their insights cover the fights against antimicrobial resistance, the potential of quantum computing and commercial space travel, and autonomous laboratories. Throughout 2021, the alliance suggests, digital transformation has continued to accelerate and the pharmaceutical industry has further embraced collaboration, both of which will underpin success in emerging areas in the next 12 months.

Linda Kasim, Empowering the Patient theme lead, Pistoia Alliance: “In 2022, there will be renewed focus on the fight against super bugs and antimicrobial resistance (AMR). This will be primarily driven by public-private partnerships, funding from philanthropic organisations, governments and international bodies to incentivise research. The public sector must quickly increase investment into AMR research, or the cost to national economies and public health could be devastating.”

Imran Haq, Emerging Science and Technology theme lead, Pistoia Alliance: “Deal making in the quantum space will continue to grow at pace in 2022. Driven by macro geopolitical trends and Big Tech, as they focus on how emerging technologies are being developed rapidly. The buzz around the sector will match this, and it will be the year we finally start to see a translation of this buzz into early versions of applications and use cases in the pharma industry."

Anca Ciobanu, Improving the Efficiency and Effectiveness of R&D theme lead, Pistoia Alliance: “Efficiency in R&D is on an exponential growth path as more pharma and biotech organisations partner with AI and robotics companies, enabling a more automated drug discovery process. In 2022, the major tech players will increase their focus on the life sciences and will play an important role in developing new products and initiatives.”

Companies